Oct. 27.-29. 2018
T004 (0051) Expression of PD-1 and PD-L1 increase in multiple consecutive biopsies in patients with classical Hodgkin lymphoma
T005 (0077) Trabectedin inhibits classical Hodgkin Lymphoma growth, monocytes immunosuppressive polarization by tumor cells and synergizes with the CCR5-antagonist Maraviroc
T006 (0079) The peripheral blood Neutrophil PD-L1 and lymphocyte PD-1 axis in classical Hodgkin lymphoma at diagnosis
T007 (0099) PD-L1+ and IDO-1+ tumor-associated macrophages predict survival in primary classical Hodgkin lymphoma
T001 (0006) CK2A is overexpressed, active and targetable with silmitasertib In classical Hodgkin Lymphoma
T002 (0076) Low B-cell content at diagnosis is associated with adverse outcome in advanced stage classical Hodgkin Lymphoma
T003 (0171) ROR-1 receptor is a potential therapeutic target in classical Hodgkin Lymphoma
T008 (0050) Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy
T009 (0083) Circulating Tumor DNA as a Biomarker for the Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
T010 (0113) Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin lymphoma patients
T011 (0162) Molecular Mechanisms in the Pathogenesis of Composite Lymphomas
P019 (0158) Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout
P021 (0168) Copy number aberrations in cell-free DNA of Hodgkin lymphoma
P004 (0011) Array-based DNA methylome analyses of classical Hodgkin lymphoma
P005 (0036) The role of TCF3 in classical Hodgkin lymphoma
P006 (0037) Recurrent exportin 1 mutations in patients with classical Hodgkin Lymphoma
P007 (0043) TARC immunohistochemistry in the diagnosis of classical Hodgkin lymphoma
P008 (0053) Whole-slide-image analysis of the tumormicronenvironment in classical Hodgkin Lymphoma
P009 (0069) CD2 is an important adhesion molecule in the initial interaction between Hodgkin Reed-Sternberg cells and rosetting T cells
P010 (0073) A new reliable and highly specific antibody to detect SOCS1 (Silencer of Cytokine Signaling 1).
P012 (0081) Soluble cytokines in Hodgkin lymphoma patients treated with a GHSG policy: an analysis of the Czech Hodgkin Lymphoma Study Group
P013 (0088) Digital image analysis of the microenvironment in classical Hodgkin lymphoma comparing primary tumor and relapse
P014 (0098) CD47 is expressed on Hodgkin Reed Sternberg cells in Classical Hodgkin lymphoma.
P015 (0100) Characterization of T-cell phenotypes with clinical significance in patients with classical Hodgkin lymphoma
P016 (0104) Phenotypic characterization of circulating T and NK cells in Hodgkin lymphoma patients in relation to tumor burden and treatment
P017 (0120) Immunologic Biomarkers of Response and Resistance to Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
P018 (0139) GATA3 expression distinguishes Classic Hodgkin lymphoma from Nodular lymphocyte Hodgkin lymphoma
P020 (0164) Extracellular ciruculating DNA in Hodgkins lymphoma patients: biological corellates and prognostic impact
P022 (0170) The Tumor Suppressor SAMHD1 is Downregulated by MYC in Classical Hodgkin Lymphoma
P031 (0145) Evaluation of CCL17 (TARC) as a diagnostic biomarker for classical Hodgkin lymphoma: interim results from the CANDEL study.
T012 (0066) Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial
T013 (0095) Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin lymphoma in the UK NCRI RAPID trial
T014 (0118) Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era
T015 (0124) Brentuximab Vedotin and AVD Chemotherapy followed by Reduced Dose/Volume Radiotherapy in Patients with Early Stage, Unfavorable Hodgkin Lymphoma
P027 (0101) Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK ‘RAPID’ Trial in Early Low-Risk Hodgkin Lymphoma
P029 (0142) Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG
P023 (0003) Conventional vs multifractionation at radiotherapy for above diaphragm stage II Hodgkin Lymphoma: 30-year experience of single Center
P024 (0009) Limited-Stage Hodgkin Lymphoma: Minimizing Toxicity
P025 (0033) Metabolic tumor volume by positron emission tomography ⁄ computed tomography for deciding the therapeutic modality in patients with early stage Hodgkin’s lymphoma
P026 (0057) Interim- PET Results for Prognosis in Adults with Hodgkin Lymphoma: A Prognostic Factor Exemplar Review (Preliminary Results)
P028 (0102) Patterns of Relapse in Patients Treated for Early Stage Classical Hodgkin Lymphoma in the Modern Era
P030 (0143) Once-a-cycle vs. daily G-CSF in early-unfavorable stages of Hodgkin Lymphoma treated with BEACOPP escalated followed by ABVD
P050 (0075) Clinical Characteristics and Prognosis Analysis of Early-Stage Classical Hodgkin Lymphoma
T016 (0018) Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials
T017 (0044) Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin lymphoma in first remission?
T018 (0140) Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators
P036 (0023) Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes
P060 (0122) The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma
P032 (0002) Audit of lymphoma patient group irradiated blood product policy compliance at a UK comprehensive cancer centre
P033 (0007) SINGLE CENTER ANALYSIS OF NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA: FOCUS ON R-ABVD AND INTERIM PET
P034 (0021) Returning to school or work after Hodgkin lymphoma: An EORTC-LYSA cross-sectional study
P035 (0022) Fatigue impairment in Hodgkin and non-Hodgkin lymphoma survivors: A joint EORTC-LYSA cross-sectional survey
P037 (0027) The pathway to diagnosis of Hodgkin Lymphoma in South Africa: the determinants and impact of diagnostic delay
P038 (0029) Hepatitis B virus infection is not associated with poor prognosis in Hodgkin lymphoma patients: A case-control study
P039 (0030) Temporal trends in treatment-related incidence of diseases of the circulatory system among Hodgkin lymphoma patients
P040 (0031) Clinicopathological features and prognosis of 387 cases with classical Hodgkin lymphoma from China
P041 (0034) A study of patient and general practitioner (GP) views and experience of managed local follow-up of long term lymphoma survivors (ADAPT)
P042 (0035) Anemia has a negative impact on the outcome of patients with Hodgkin lymphoma
P043 (0039) Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: A retrospective study of 27 cases
P044 (0046) Investigation the role of adding a serum biomarker to interim PET/CT in Hodgkin lymphoma patients
P045 (0047) Hyperlipoproteinemia and markers of atherosclerosis progression in long-term survivors of Hodgkin lymphoma in childhood or adolescence and in healthy controls
P046 (0052) No clinical signals of Drug – Drug interaction of NEPA (netupitant + palonosetron) in cHL patients receiving ABVD regimen: a single-center real life experience
P047 (0058) An Epidemiological Study of Hodgkins Lymphoma from a single tertiary care centre in India with study of disease outcome
P048 (0065) Mature oocytes cryopreservation: a feasible fertility preservation technique in adult Hodgkin lymphoma female patients.
P049 (0072) Results of cardiovascular screening in the BETER survivorship care initiative for Hodgkin lymphoma
P051 (0080) Cardiovascular disease risk after treatment-induced premature ovarian insufficiency in female survivors of Hodgkin lymphoma
P052 (0082) Combined prognostic role of biomarkers and PET/CT in patients with Hodgkin lymphoma
P053 (0091) NEUTROPHIL TO LYMPHOCITE RATIO PREDICTS OVERALL SURVIVAL IN NEWLY DIAGNOSED HODGKIN LYMPHOMA PATIENTS - SINGLE CENTRE EXPERIENCE
P054 (0092) Pregnancy in patients in complete remission after Hodgkin Lymphoma: clinical features and outcome.
P055 (0096) Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL)
P056 (0097) Cognitive Dysfunction after Treatment for Hodgkin lymphoma
P057 (0108) Cognitive impairments in patients with Hodgkin’s Lymphoma
P058 (0109) Fertility in Hodgkin´s lymphoma patients after initial therapy at Santa Casa de São Paulo Medical School
P059 (0114) AA Amyloidosis Causing Nephrotic Syndrome in Two Patients with Hodgkin Lymphoma
P061 (0125) Chemotherapy-induced polyneuropathy in patients with Hodgkin lymphoma treated with vinca-alkaloids
P062 (0134) Long term health care use in relapsed and non-relapsed paediatric and young adult Hodgkin lymphoma patients – a population-based cohort study from Sweden and Denmark
P063 (0144) Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First interim results of ongoing translational study.
P064 (0146) Cause-specific mortality among Hodgkin lymphoma survivors up to 35 years after treatment
P065 (0150) Elevated neutrophil-to-monocyte ratio is associated with decreased overall survival at 5 years in classic Hodgkin lymphoma
P066 (0154) eBEACOPP FOR FRONT-LINE TREATMENT OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (cHL) IN THE REAL WORLD SETTING
T019 (0026) Potential impact of consolidation radiation therapy for advanced Hodgkin Lymphoma: a secondary modeling analysis of SWOG S0816
T020 (0067) Baseline PET features as predictors of outcome in advanced HL : A prospective evaluation of UK patients in the RATHL trial (CRUK/07/033)
T021 (0147) B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)ne) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)
P068 (0008) JUNB, DUSP2, SGK1, CREBBP and SOCS1 are frequently mutated in T-cell/histiocyte rich large B-cell lymphoma
P069 (0013) EVALUATION OF CLINICAL CHARACTERISTICS IN PATIENTS WITH INTERIM-PET NEGATIVE BUT POSITIVE END OF TREATMENT PET. DATA FROM THE PROSPECTIVE HD08-01 FIL STUDY.
P070 (0016) HIV-Associated Hodgkin Lymphoma at Groote Schuur Hospital, Cape Town, South Africa
P071 (0024) A Multicenter Phase 2 Study of Sequential Brentuximab Vedotin and AVD Chemotherapy for Older Patients with Untreated Classical Hodgkin Lymphoma
P072 (0038) FRONTLINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY EXHIBITS SUPERIOR MODIFIED PROGRESSION-FREE SURVIVAL VS CHEMOTHERAPY ALONE IN PATIENTS WITH STAGE III OR IV HODGKIN LYMPHOMA: PHASE 3 ECHELON-1 STUDY
P073 (0045) BEACOPP escalated increases progression free survival in advanced classic Hodgkin lymphoma - a single centre real life experience
P074 (0049) Accuracy of PET-based bone marrow assessment in patients with Hodgkin lymphoma: Results from the German Hodgkin Study Group trials HD16, HD17, and HD18
P075 (0055) Should a bulky mediastinal mass larger than 7cm be considered an adverse prognostic factor in patients with advanced Hodgkin lymphoma and negative interim PET/CT?
P076 (0056) Clinical characteristics and treatment outcome of Nodular Lymphocyte Predominant Hodgkin's lymphoma with THRLBCL-like patterns.
P077 (0060) Comparison immunoarchitectural patterns of primary, extranodal and bone marrow lesions in nodular lymphocyte predominant Hodgkin lymphoma.
P078 (0062) Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease
P079 (0070) German evidence-based guideline update on diagnosis, therapy and follow-up of adult Hodgkin lymphoma patients
P080 (0071) Analysis of outcomes and prognostic factors of 165 newly diagnosed patients with advanced classical Hodgkin lymphoma
P081 (0084) A Clinicopathologic Consensus Study of Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-cell Lymphoma (DLBCL) and Classical HL (cHL)
P082 (0087) Clinical significance of autoimmune hemolytic anaemia and autoimmune thrombocytopenia during the course of Hodgkin lymphoma
P083 (0093) Low-dose consolidative mediastinal irradiation in accelerated hyperfractionated regimen for advanced Hodgkin lymphoma
P084 (0094) Brentuximab-Vedotin and Bendamustine as first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).
P085 (0112) Treatment toxicity in elderly Hodgkin lymphoma patients with advanced stage – multicenter retrospective data analysis from the Czech Republic
P086 (0129) Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
P087 (0135) HODGKIN LYMPHOMA IN HIV-POSITIVE PATIENTS: A SINGLE INSTITUTION RETROSPECTIVE STUDY
P088 (0136) BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA (CHL): RESULTS OF PRESPECIFIED SUB-GROUP ANALYSES FROM THE ECHELON-1 STUDY
P089 (0137) POPULATION PHARMACOKINETIC (POPPK) MODELING AND EXPOSURE-RESPONSE (ER) ASSESSMENT OF BRENTUXIMAB VEDOTIN EFFICACY AND SAFETY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA (CHL) FROM THE PHASE 3 ECHELON-1 STUDY
P090 (0141) PET-CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma (HL).
P091 (0159) SERUM sCD30 AND TARC DO NOT CORRELATE WITH PET-BASED RESPONSE ASSESSMENT IN PATIENTS (PTS) WITH STAGE III OR IV CLASSICAL HODGKIN LYMPHOMA (cHL): PHASE 3 ECHELON-1 STUDY OF BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY VS CHEMOTHERAPY ALONE
T022 (0042) Survival by race/ethnicity in pediatric and adolescent patients with Hodgkin lymphoma: A pooled analysis of contemporary Children’s Oncology Group trials
T023 (0106) Safety and early response to the first 2 cycles of Brentuximab Vedotin substituting vincristine in the OEPA / COPDAC regimen for high risk pediatric Hodgkin Lymphoma (HL)
T024 (0123) The feasibility of deep inspiration breath-hold in children: Results of the TEDDI pilot study
P092 (0019) Proteomic identification of plasma biomarkers in children and adolescents with recurrent Hodgkin Lymphoma
P093 (0028) HOPE to COPE with OPPA/COPP: Experience of GPOH HD-2002 study protocol in Pediatric Hodgkin Lymphoma in a tertiary care hospital in a resource constraint setting
P094 (0059) KEYNOTE-667: Phase 2, Open-Label Study of Pembrolizumab in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) With Slow Early Response (SER) to Frontline Chemotherapy
P095 (0064) Hodgkin’s Lymphoma in adolescents: the Italian Association of Pediatric Hematology and Oncology (AIEOP) experience.
P096 (0085) M1 macrophage polarization prevails in pediatric Hodgkin Lymphoma from Argentina regardless of Epstein Barr virus presence.
P097 (0105) Implementing an effective pre-accrual quality assurance programme in the UK to ensure accuracy and consistency of radiotherapy contouring for paediatric Hodgkin’s Lymphoma within the EuroNet-PHL-C2 trial (EudraCT 2012-004053-88)
P098 (0111) Treatment outcomes of Adolescent and young adult (AYA) Hodgkin lymphomas (HL): real world data from a tertiary care cancer centre
P099 (0117) Survival by age in children and adolescents with Hodgkin lymphoma: A pooled analysis of Children’s Oncology Group (COG) trials
P100 (0119) FAMHL: Genetic Study of Families with a High Frequency of classical Hodgkin Lymphoma
P101 (0149) PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN PLUS AVD IN PEDIATRIC PATIENTS WITH ADVANCED STAGE NEWLY DIAGNOSED CLASSICAL HODGKIN LYMPHOMA
P102 (0151) Durable remission for two patients with early relapse of Hodgkin lymphoma, treated with Brentuximab Vedotin plus Gemcitabine, without autologous stem cell transplantation: a report from the Children’s Oncology Group
P103 (0152) Stanford V chemotherapy and low dose radiotherapy for children and adolescents with unfavorable and intermediate risk Hodgkin lymphoma: results of a multi-institutional prospective clinical trial
T025 (0005) Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma: follow-up results from the phase 1/2 study
T026 (0025) A Phase II study of SHR-1210, an anti-PD-1 antibody, in Chinese Patients with Relapsed/Refractory classic Hodgkin Lymphoma
T027 (0153) Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years
T028 (0163) Allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory classical Hodgkin Lymphoma (cHL) patients treated with Nivolumab is associated with an unprecedented low relapse rate
P105 (0032) A phase II study of Pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (cHL): interim results
P104 (0004) Nivolumab in relapsed/refractory classic Hodgkin lymphoma: Experience with ten patients
P106 (0131) Clinical benefit of Nivolumab in Hodgkin Lymphoma but at what price? Example into a Paris University Hospital
P107 (0155) Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma: Updated Efficacy and Safety Analysis of the Phase 2 KEYNOTE-087 Study
T029 (0010) Second Autologous Stem Cell Transplantation (ASCT) for Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
T030 (0103) Bendamustine, Gemcitabine, and Dexamethasone (BGD) Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) Is Effective Treatment for Patients with Relapsed/Refractory Hodgkin Lymphoma (rHL) – Results of the Polish Lymphoma Research Group
T031 (0110) Five-Year Progression-Free Survival Outcomes From a Pivotal Phase 3 Study of Consolidative Brentuximab Vedotin After Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression (AETHERA).
T032 (0130) Relapse after Early-Stage Favorable Hodgkin Lymphoma: Disease Characteristics, Treatment Strategies and their Outcome
P118 (0068) Long Term Safety and Efficacy of Combination of Brentuximab Vedotin and Ipilimumab or Nivolumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412)
P126 (0121) PD-1 blockade for Hodgkin Lymphoma after Allogeneic Stem Cell Transplantation
P067 (0166) VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY
P108 (0001) Allogeneic stem cell transplantation after treatment with checkpoint inhibitors: feasibility and safety in pooled analysis
P109 (0012) High CR rate in Interim Results of a phase II trial of Nivolumab with or without ICE in relapsed/refractory HL prior to AHCT
P110 (0014) Successful treatment of Hodgkin lymphoma with brentuximab vedotin relapsing after autologous stem cell transplantation
P111 (0017) Time to relapse in nodular lymphocyte-predominant Hodgkin lymphoma is related to the histopathological pattern at initial diagnosis and relapse
P112 (0020) A PHASE II STUDY WITH BENDAMUSTINE PLUS BRENTUXIMAB VEDOTIN IN HODGKIN’S LYMPHOMA IN FIRST SALVAGE SETTING: THE BBV REGIMEN.
P113 (0040) Phase I/II study of Brentuximab Vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation.
P114 (0041) Results of Mini-BEAM as second salvage chemotherapy after DHAP based chemotherapy for relapsed or refractory classical Hodgkin lymphoma
P115 (0048) Brentuximab vedotin (BV) as maintenance or salvage therapy after ASCT for relapsed/refractory (R/R) HL
P116 (0054) EARLY TRANSPLANT RELATED COMPLICATIONS IN HODGKIN LYMPHOMA PATIENTS RECEIVING PD-1 INHIBITORS BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION
P117 (0063) BENDAMUSTINE IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS
P119 (0078) Real life data of brentuximab vedotin use in relapsed/refractory HL in Sweden
P120 (0086) Outcomes and Toxicities after Brentuximab vedotin (BV) Maintenance in Relapsed/Refractory Hodgkin Lymphoma Patient Exposed to BV prior to Autologous Hematopoietic Stem Cell Transplant
P121 (0089) Sequential time-intensified brentuximab vedotin (BV) followed by gemcitabine, vinorelbine and pegylated liposomal doxorubicine (GVD) as a bridge to autologous transplantation in DHAP resistant relapsed or refractory CD30+ lymphoma
P122 (0090) BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC TRANSPLANTATION IN HODGKIN’S LYMPHOMAS REDUCES CHRONIC GVHD WITHOUT WORSENING THE OUTCOME
P123 (0107) Next generation sequencing-based clonality assessment of immunoglobulin gene rearrangements distinguishes relapse from second primary Hodgkin lymphoma
P124 (0115) RETROSPECTIVE REAL-LIFE STUDY OF THE BEGEV (BENDAMUSTINE, GEMCITABINE, VINORELBINE) REGIMEN IN HEAVILY PRETREATED, RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
P125 (0116) Nivolumab Re-Treatment in Patients With Relapsed/Refractory Hodgkin Lymphoma
P127 (0126) Autologous (auto-HCT) and Allogeneic Stem Cell Transplantation (allo-HCT) in the Management of Relapsed/Refractory (RR) Hodgkin Lymphoma (HL). A Retrospective Analysis of the Lymphoma Working Party of the EBMT.
P128 (0127) SUCCESFUL SLOW DESENSITIZATION TO BRENTUXIMAB VEDOTIN AFTER ANAPHYLAXIS: 3 CASE REPORTS IN THE BASQUE AUTONOMOUS COMMUNITY
P129 (0128) Clinical analysis of relapse patterns in Hodgkin Lymphoma
P130 (0132) PRIMARY PROGRESSIVE CLASSICAL HODGKIN LYMPHOMA – A SINGLE CENTRE EXPERIENCE
P131 (0133) Pooled results of two annual cohorts from an observational prospective study describing brentuximab vedotin use in routine practice in France for Hodgkin Lymphoma: Interim analysis.
P132 (0138) Patterns and Outcomes with Salvage Treatment for Hodgkin Lymphoma (HL) in the Modern Era: A Real-World Analysis from the Community Oncology Setting in the United States
P133 (0148) PROGNOSTIC VALUE OF (18) F-FLUORODEOXYGLUCOSE-POSITRON EMISION TOMOGRAPHY ON SURVIVAL IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ALLOGENEIC STEM CELL TRANSPLANTATION.
P134 (0156) Induction therapy with everolimus in combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in patients with relapsed or refractory classical Hodgkin lymphoma: a randomized, placebo-controlled phase I/II trial (HD-R3i)
P135 (0160) Brentuximab-Vedotin + Bendamustine : a highly effective salvage treatment un refractory/relapsed patients with Hodgkin Lymphoma
P136 (0161) Long term outcome of patients with relapsed / refractory Hodgkin lymphoma treated at a single institution over 25 years
P137 (0165) TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF VERY LATE RELAPSES (VLRs) OCCURRING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOINT STUDY FROM THE UNIVERSITY OF ATHENS AND ISTITUTO
P138 (0167) Long-term High Dose Chemotherapy Before Hematopoietic Stem Cell Transplantation due to Restricted Access to New Therapies
P139 (0169) Brentuximab vedotin alone and in combination with bendamustine as salvage therapy for primary refractory or relapsed Hodgkin lymphoma: multicentre experience of the Polish Lymphoma Research Group
Gürzenich Cologne Martinstraße 29-37 50677 Cologne During the Conference the Secretariat can be contacted at Phone: +49 (0) 173 939 07 30 Email: firstname.lastname@example.org
Saturday, 27.10.2018 07:00–18:00 Sunday, 28.10.2018 07:00–19:00 Monday, 29.10.2018 07:00–18:00
If you are still in need of a hotel room, please contact the conference management: Phone: +49 (0) 173 939 07 30 Email: email@example.com
Please make sure to always wear your badge at the conference. If you lose your badge, we will have to charge you a replace- ment fee.
During the breaks, complimentary co ee, fruit and refreshments will be available, and other small snacks can be bought. For participants of the scientific symposia, breakfast and lunch will be provided.
The cloakroom is located in the basement.
The conference language is English.
The meeting organizers cannot accept liability for personal injuries sustained to congress participants or for loss or damage of their personal belongings, neither during nor as a result of the meeting.
There will be free WIFI at the Gürzenich Conference Center. Further details and access codes will be provided on site. You can also use the two on-site internet terminals for web browsing and web-based email access.
Pre-registration will close on October 26, 2018. All registrations received on or after October 27 will be considered as on-site registrations and will be charged the on-site fee. Full registration will include access to the scientific sessions and exhibition, a copy of the program, the welcome reception on Saturday (October 27) and all refreshment breaks. You will also receive a name tag; please wear this name tag at all conference events including the scientific symposia. No refunds will be given.
The Speakers Ready Room is located next to the registration desk on the ground floor of the Gürzenich Conference Center. Speakers are requested to hand in their PowerPoint presentations in 16:9 format saved on a stick at least 3 hours before their session or the day before if the session starts early in the morning. We can only accept Windows PowerPoint files for upload to the conference system. It is not permitted to use your own laptops or other devices for uploading the files.
Please note that there will be a strict non-smoking policy at all conference facilities.
On Saturday evening, the conference will be opened officially. After the Opening Ceremony, all participants are warmly invited to join us at our Get Together event at the Gürzenich Conference Center. This event is a great opportunity to meet and chat with many colleagues involved in Hodgkin Lymphoma research and treatment. Drinks and snacks will be provided.
We wish to express our appreciation and gratitude to our partners.
Financial support was kindly provided by the Deutsche Forschungsgemeinscha (DFG) within their programme „International Scientific Events“
The Karl Musshoff Stiftung kindly supports the Karl-Musshoff-Price for both, the best basic science abstract and best clinical abstract.
Accreditated by "Ärztekammer Nordrhein"
Certified with 23 credit points by the European Association for Haematopatology (EAHP)
The ONKO-Internetportal in cooperation with Deutsche Krebsgesellschaft e.V. is our media cooperation partner.
ECP 2018 will be held from 8 to 12 September 2018 at the Euskalduna Conference Centre next to the river Nervión.
Global Congress on Molecular Pathology: Evidence-based Precision Medicine May 16 - 18, 2019 in Hong Kong
Prof. Dr. Andreas Engert German Hodgkin Study Group (GHSG) Gleueler Str. 269-273 50935 Köln Phone: +49 (0)221-478 5933 Fax: +49 (0)221-478 3778
In accordance with the German Act for Telemedia Services (TMG), § 55 Abs. 2 RStV (section 55, subsection 2 broadcast services state treaty): Prof. Dr. Andreas Engert
Legal Entitiy: The University Hospital of Cologne is a Public Law Institution. Legal Representation: The University Hospital of Cologne is represented by the Board of Directors, in turn represented by: Prof. Dr. Edgar Schömig, CEO and medical director Günter Zwilling, Director of finance Kerpener Str. 62 D-50937 Köln